Sudarshan Pharma Med Therapy 9.5% Acquisition Update

Company Acquisition:

Proposal to acquire 9.50% equity shares of common stock of Med Therapy Biotechnology Inc., USA
Status: Under due diligence process
Pending: Confirmation from Med Therapy Board of Directors decision
Pending: Board of Directors resolution from Med Therapy
Current status: Proposal intimated only, with updates to follow

Promoter Acquisitions:

Mr. Hemal Mehta (Chairman & Managing Director) proposing to acquire 1.50% equity shares
Mr. Sachin Mehta (Joint Managing Director) proposing to acquire 1.50% equity shares
Both promoters are promoters of Sudarshan Pharma Industries Limited
Status: Under due diligence process
Pending: Confirmation from Med Therapy Board of Directors decision
Pending: Board of Directors resolution from Med Therapy
Current status: Proposal intimated only, with updates to follow

Financial impact not quantified in the disclosure. The acquisition proposals remain subject to due diligence and board approvals.